{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001677","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.085352+00:00","generated_at":"2026-06-08T12:14:41.978286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q3 revenue up 7% to $3.9B, raises FY revenue guidance to $15.1-$15.5B","bullets":["Revenue $3.85B (+7% YoY); GAAP EPS $0.07, non-GAAP EPS $0.60.","Raised 2023 revenue outlook to $15.1-$15.5B from $15.0-$15.4B; reaffirms non-GAAP EPS $2.25-$2.55.","AUSTEDO and AJOVY drove growth; global generics revenues increased across all segments.","Entered exclusive collaboration with Sanofi on Anti TL1-A (TEV-'574) in October 2023.","Appointed Dr. R. Ananthanarayanan as CEO of Teva api; olanzapine LAI Phase 3 results now H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001677","json":"https://secwatch.observer/filing/0001157523-23-001677.json","markdown":"https://secwatch.observer/filing/0001157523-23-001677.md","text":"https://secwatch.observer/filing/0001157523-23-001677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/0001157523-23-001677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/a53780340.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T12:14:41.978286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fdcfee0a8b8d61d3a6362a2209adb39ee14591d8","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2023 results: revenue $3.9 billion, EPS GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60. Guidance raised.","evidence_excerpt":"Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ® , AJOVY ® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/0001157523-23-001677-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$3.9 billion"},{"label":"EPS","value":"GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}